Search Results - L. B. Egoryan
- Showing 1 - 3 results of 3
-
1
-
2
Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study by O. Yu. Vinogradova, M. M. Pankraskina, A. L. Neverova, D. I. Shikhbabaeva, M. A. Murzabekova, M. V. Chernikov, A. V. Popova, V. P. Kosenkova, L. B. Egoryan, V. V. Ptushkin
Published 2024-09-01
Article -
3
Molecular markers as possible efficacy predictors of targeted therapy for myelofibrosis: single-center study by O. Yu. Vinogradova, D. I. Shikhbabaeva, Yu. N. Kobzev, A. L. Neverova, M. M. Pankraskina, S. G. Malakho, M. V. Chernikov, M. A. Murzabekova, A. G. Popova, L. B. Egoryan, A. V. Krechetova, V. V. Ptushkin
Published 2023-12-01
Article